The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Cipla has a robust governance model focused on sustainability
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Subscribe To Our Newsletter & Stay Updated
